NEW YORK--(BUSINESS WIRE)--Aug. 28, 2006--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or “The Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, today announced the appointment of Nanci I Prado as Vice President and General Counsel. Ms. Prado will report to Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, and will oversee the Company’s corporate, securities compliance, governance and general legal matters.
